Last Update

2016-02-12T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Jonathan Ratner?

Dr. Jonathan Ratner

Senior Economist

Westat Inc

Direct Phone: (301) ***-****       

Email: j***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Westat Inc

1650 Research Blvd.

Rockville, Maryland 20850

United States

Company Description

Westat is an employee-owned corporation providing research services to agencies of the U.S. Government, as well as businesses, foundations, and state and local governments. In addition to capabilities as a leading statistical survey research organization, ... more

Find other employees at this company (2,547)

Background Information

Employment History

Economist and Assistant Director and Associate Director

GAO

Assistant Professor of Economics

Wellesley College

Assistant Professor

State University of New York at Albany

Affiliations

Staff Member for the Finance Committee
U.S. Senate

Education

PhD

Web References (16 Total References)


What's New in Clinical Trials at Westat

www.westat.com [cached]

06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting

...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.


What's New in Clinical Trials at Westat

www.westat.org [cached]

06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting

...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.


What's New in Clinical Trials at Westat - 2010 News Archive

www.westat.com [cached]

06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting

...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.


Westat | Clinical Trials |2010 News, Awards, Presentations

www.westat.com [cached]

06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting

...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.


Westat | Clinical Trials |2010 News, Awards, Presentations

www.westat.com [cached]

06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting

...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.

Similar Profiles

Other People with this Name

Other people with the name Ratner

Hilary Ratner
Wayne State University

Ronald Ratner
National Multi Housing Council

Mark Ratner
Hawthorne Direct Inc

Naomi Ratner
Hermann Realtors

Hal Ratner
Morningstar, Inc.

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory